Category: Parkinsonism, Atypical: MSA
Objective: In multiple system atrophy (MSA) patients to: 1) evaluate 18F-PBR06 positron emission tomography (PET) for longitudinal assessment of 18-kilodalton-translocator protein (TSPO) binding; 2) assess relationship of PET with clinical parameters and automated 3D volumetric segmentation of defined brain regions; and 3) determine pharmacodynamic effects of verdiperstat, an orally administered myeloperoxidase inhibitor.
Background: Neuroinflammation and focal cerebral volume loss are hallmarks of MSA and track with clinical subtype and can be measured in vivo with 18F-PBR06, a second-generation TSPO radioligand for assessment of cerebral microglial activation1, and 3D-MRI volumetric segmentation2. Verdiperstat is being developed as a treatment for neurodegenerative diseases; a Phase 3 trial in MSA is ongoing (NCT03952806).
Method: 20 patients with clinically probable MSA-P or MSA-C are planned to be enrolled in this study, which has observational and treatment phases (NCT04616456). Observational: patients undergo clinical (Unified MSA Rating Scale [UMSARS] and Brief Ataxia Rating Scale [BARS]), PET and MRI assessments at entry and 6-9 months. Biospecimens (blood, stool, skin biopsy and CSF) are collected. Treatment: patients are treated with verdiperstat 600-mg twice daily for 6-months and clinical, PET, MRI and biospecimens are subsequently obtained. Standardized Uptake Value Ratios (SUVRs) are normalized to global brain SUV for the 60-90 minute PET frames. FreeSurfer is used for automatic volumetric segmentation of high-resolution isotropic T1 MRI images.
Results: Four female probable MSA-C patients (UMSARS Part I: 7-26; Part II:12.5-21; BARS: 9.5-15.5) were enrolled in the observational phase. Putaminal SUVRs were significantly elevated in MSA patients vs. controls (p<0.01). One subject (‘MSA-03’) experienced significant clinical decline over the observation period. Blinded assessment of volumetric MRI and 18F-PBR06 singled out progression in these imaging parameters. A linear decrease in volume of multiple deep gray structures, pons, and cerebellum was noted over time.
Conclusion: This is the first study to evaluate the role of 18F-PBR06 PET in MSA and will provide data on the pharmacodynamic effects of verdiperstat in MSA, complementing the ongoing Phase 3 trial.
References:  Fujimura et al. J Nucl Med 2009 Jul;50(7):1047-53  Scherfler, C, et al. Neurology. 2016 Mar29;86(13):1242-9
To cite this abstract in AMA style:T. Singhal, A. Pitaro, J. Kim, J. Woods, M. Mesidor, J. Ficke, A. Willett, S. Cicero, K. O'Connor, I. Qureshi, G. Young, V. Khurana. Longitudinal 18F-PBR06 (TSPO) and Volumetric MR Imaging as Pharmacodynamic Endpoints for MSA – Ongoing Investigator Sponsored Trial of Verdiperstat [abstract]. Mov Disord. 2021; 36 (suppl 1). https://www.mdsabstracts.org/abstract/longitudinal-18f-pbr06-tspo-and-volumetric-mr-imaging-as-pharmacodynamic-endpoints-for-msa-ongoing-investigator-sponsored-trial-of-verdiperstat/. Accessed December 7, 2023.
« Back to MDS Virtual Congress 2021
MDS Abstracts - https://www.mdsabstracts.org/abstract/longitudinal-18f-pbr06-tspo-and-volumetric-mr-imaging-as-pharmacodynamic-endpoints-for-msa-ongoing-investigator-sponsored-trial-of-verdiperstat/